Clinical trial NCT06045910: A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Official title: A Cancer Research UK Phase I/II Trial of ALETA-001 in Participants Who Have Received an Anti-CD19 CAR T-Cell Therapy for the Treatment of B-cell Malignancies
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Mantle-Cell
Lymphoma, Follicular
Lymphoma, B-Cell
Large B-cell Lymphoma
Keywords: Neoplasms
Immunotherapy, Adoptive
Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell
Antigens, CD19
Lead sponsor: Cancer Research UK
Sponsor class: OTHER
Collaborators: name: Aleta BioTherapeutics
First posted: 2023-09-21
Enrollment: 84
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase I/II multicentre, open-label trial designed to evaluate the efficacy, safety, tolerability, timing of administration and pharmacokinetics (PK) of a novel chimeric antigen receptor (CAR) T-cell engager, ALETA-001, administered by intravenous (IV) infusion as a single agent every 2 weeks in participants with B-cell malignancies post CD19 CAR T-cell therapy. This first in human study is divided into 2 parts: a safety lead-in phase (Phase I) and a dose expansion phase (Phase II). Different dose levels of ALETA-001 and timing of administration will be evaluated in Phase I in order to define a recommended dosing level and time of administration for Phase II. Phase II will further evaluate the safety, PK and therapeutic activity of ALETA-001.


Eligibility criteria: Inclusion Criteria:

For all participants

Criteria to be met prior to enrolment in the trial:

* Aged 16 years or over.
* Written (signed and dated) informed consent and be capable of co-operating with ALETA-001 administration and follow-up.
* Confirmed diagnosis of B-cell NHL according to World Health Organization (WHO) 2016 criteria.
* Eastern Cooperative Oncology Group performance status of 0, 1 or 2.
* Biochemical indices within protocol specified ranges.

Cohort Specific Inclusion criteria (for Phase I Cohorts A \& B) Criteria to be met prior to enrolment in the trial.

* Histologically confirmed diagnosis of relapsed/refractory LBCL or MCL.
* Have received an approved anti-CD19 CAR T-cell therapy.
* Objectively evaluable or measurable disease at 4 weeks (±1 week) post CAR T, which demonstrates:

  * inadequate or incomplete response (PR or SD), or
  * PD if there is a reasonable expectation of deriving benefit from trial treatment, or
  * initial response followed by relapse within 9 months assessed according to Lugano Criteria.
* Haematological indices within protocol specified ranges.

Cohort Specific Inclusion criteria (for Phase I Cohorts C \& D) Criteria to be met prior to lymphodepleting chemotherapy for CAR T therapy.

* Histologically confirmed diagnosis of relapsed/refractory LBCL or MCL.
* Approved by the UK national CAR T Clinical Panel (NCCP) to receive an approved anti-CD19 CAR T-cell therapy.
* Haematological indices within protocol specified ranges.
* Adequate cardiac function within protocol specified ranges with no clinical symptoms or signs of heart failure.
* Resting O2 saturation of ≥92% on room air.

Eligibility for participants in Phase II of the trial will depend on timing of administration of ALETA-001 which will be recommended by the Safety Review Committee (SRC).

Exclusion Criteria for all participants:

* Active or previous malignancies of other types that, in the opinion of the Investigator, should exclude the participant. Exceptions include adequately treated cone biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin and patients with asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or who require only hormonal therapy and have had normal prostate specific antigen for \>1 year prior to the start of therapy. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for 2 years or more and are deemed at negligible risk for recurrence, are eligible for the trial.
* Any ongoing toxic manifestation of previous anti-cancer treatment that, in the opinion of the Investigator, should exclude the participant.
* Ongoing need for systemic immunosuppressive therapy other than replacement dose of corticosteroids. Intermittent topical, inhaled or intranasal corticosteroids are permitted.
* Presence of active infections and/ or inflammatory disease requiring active management.
* Documented current central nervous system involvement by lymphoma.
* Women of childbearing potential (or are already pregnant or lactating) unless willing to adhere to protocol-defined contraceptive requirements.
* Male patients with partners of childbearing potential unless willing to adhere to protocol-defined contraceptive requirements.
* Major thoracic or abdominal surgery from which the participant has not yet recovered.
* At high medical risk because of non-malignant systemic disease including active uncontrolled infection.
* Hypersensitivity to any of the ingredients/excipients in ALETA-001.
* Participation in another interventional clinical trial, whilst taking part in this trial of ALETA-001. Participation in an observational trial or interventional clinical trial that does not involve administration of an IMP and that would not place an unacceptable burden on the participant, in the opinion of the Investigator and CDD, would be acceptable.
* Participants with any congenital or acquired immunodeficiency syndrome or who are receiving immunosuppressive therapy (including any dose of systemic corticosteroids), or who are immunosuppressed post organ transplant. However, participants receiving inhaled corticosteroids and participants with a history of allergy (other than anaphylaxis) are eligible, as are participants with a history of autoimmune disease.
* Any other condition that, in the Investigator's opinion, would mean that the trial is not in the best interests of the participant.
* Concurrent radiotherapy (except for palliative reasons).

Cohort specific exclusion criteria prior to enrolment in the trial (for Phase I

Cohorts A \& B):

* Participants who have received any other systemic anti-cancer treatment post-CAR T.
* Potential participants who experienced any of the following because of the initial CAR T treatment:

  * Grade 4 CRS or ICANS post CAR T infusion.
  * Grade ≥3 CRS or ICANS persisting beyond 7 days despite optimal therapy.
  * Any Grade ≥1 CRS or ICANS must have fully resolved.
* Any Grade ≥3 organ toxicity (other than haematologic toxicity) following CAR T infusion must have improved to Grade ≤2 for at least 48 hours prior to ALETA-001 infusion.

Cohort specific exclusion criteria prior to ALETA-001 infusion between Day 10-18 post CAR T-cell infusion (for Phase I Cohorts C \& D):

* Grade 4 CRS or ICANS post CAR T infusion.
* Grade ≥3 CRS or ICANS persisting beyond 7 days despite optimal therapy.
* Any Grade ≥2 CRS or ICANS must have improved to Grade ≤1 for at least 48 hours prior to ALETA-001 infusion.
* ECOG performance status ≥3.
* Any Grade ≥3 organ toxicity (other than haematologic toxicity) following CAR T infusion must have improved to Grade ≤2 for at least 48 hours prior to ALETA-001 infusion.
* Any unresolved serious active infection which in the opinion of the Investigator precludes ALETA-001 infusion (ongoing need for IV antimicrobial therapy per se is not an exclusion).

Primary outcomes:
measure: Dose level of ALETA-001 and timing of administration for use in Dose Expansion (Safety Lead-in Phase).
timeFrame: Day 1 to Day 28.
measure: Number of Participants who experience dose limiting toxicities (DLTs).
timeFrame: Up to Day 28.
measure: Number of Participants who experience Grade 3, 4 or 5 related adverse event (AEs).
timeFrame: Safety data will be collected from the time of informed consent until 95 days after the last dose of ALETA-001. The average time from consent to the end of follow up will be presented.
measure: Best Overall Response (Dose Expansion Phase).
timeFrame: Radiological assessment from within 28 days before starting ALETA-001 and up to 12 months after.
measure: Progression-Free Survival (PFS) (Dose Expansion Phase).
timeFrame: From date of first dose of ALETA-001 up to 12 months.
measure: Time to Progression (TTP) (Dose Expansion Phase).
timeFrame: From date of first dose of ALETA-001 up to 12 months.
measure: Overall Survival (OS) (Dose Expansion Phase).
timeFrame: Follow-up until end of trial, estimated to be up to 48 months.
Secondary outcomes:
measure: Best Overall Response (Safety Lead-in Phase).
timeFrame: Radiological assessment from within 28 days before starting ALETA-001 and up to 12 months after.
measure: Progression-Free Survival (PFS) (Safety Lead-in Phase).
timeFrame: From date of first dose of ALETA-001 up to 12 months.
measure: Time to Progression (TTP) (Safety Lead-in Phase).
timeFrame: From date of first dose of ALETA-001 up to 12 months.
measure: Overall Survival (OS) (Safety Lead-in Phase).
timeFrame: Follow-up until end of trial, estimated to be up to 48 months.
measure: Maximum observed serum concentration (Cmax) of ALETA-001.
timeFrame: Day 1 to Day 7.
measure: Terminal elimination half-life (t1/2) of ALETA-001.
timeFrame: Day 1 to Day 7.
measure: Area under the concentration-time curve (AUC) of ALETA-001.
timeFrame: Day 1 to Day 7.
measure: Volume of distribution (Vss) of ALETA-001.
timeFrame: Day 1 (before first ALETA-001 infusion) to Day 7.
measure: Clearance (CL) of ALETA-001.
timeFrame: Day 1 to Day 7.
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: University Hospital Birmingham NHS Foundation Trust
city: Cambridge
country: United Kingdom
facility: Cambridge University Hospitals
city: Leeds
country: United Kingdom
facility: St James's University Hospital
city: London
country: United Kingdom
facility: University Hospital London Hospital
city: Manchester
country: United Kingdom
facility: Manchester Royal Infirmary
city: Manchester
country: United Kingdom
facility: The Christie Hospital
city: Sutton
country: United Kingdom
facility: Royal Marsden Hospital
Study officials:
affiliation: University Hospital Birmingham NHS Foundation Trust
name: Sridhar Chaganti, Dr
role: PRINCIPAL_INVESTIGATOR
References: